LOGO Myocardial Extracellular Matrix Remodeling in Heart Failure 王小蕾高新营王洁王淳阅石琳.

Slides:

Advertisements

Similar presentations

HEART FAILURE (HF) Heart failure is the pathophysiological state in which an abnormality of cardiac function is responsible for failure of the heart to.

Advertisements

Advanced Heart Failure: My Approach

PATHOPHYSIOLOGY HF/AHF Disease Awareness. HF=heart failure; LV=left ventricular 1. Alla et al. Heart Fail Rev 2007;12:91–5; 2. Gheorghiade et al. Am J.

Metastasis. Mechanisms of Invasion and Metastasis.

Molecular basis of dilated cardiomyopathy Prasad Gunaruwan 21 st June 2011.

04/19/10 EXTRACELLULAR MATRIX PROTEINS AND PROTEINASES By, Raghu Ambekar Photonics Research of Bio/nano Environments Department of Electrical & Computer.

Fig Simplified drawing of a cross-section through part of the wall of the intestine. Each tissue is an organized assembly of cells held together.

ECM degradation Artery ligation Necrotic tissue Fibroblasts Neutrophils Macrophages Pro-inflammatory cytokines Collagen C-terminus collagen peptides Pro-fibrotic.

Tissue Repair Dr. Raid Jastania. What is Repair? When does regeneration occur? When does fibrosis occur? What are the consequences of fibrosis?

1 Cardiac Pathophysiology Part B. 2 Heart Failure The heart as a pump is insufficient to meet the metabolic requirements of tissues. Can be due to: –

Heart Remember or cardiac memory.  Background Can heart remember?

Bio-Med 350 Normal Heart Function and Congestive Heart Failure.

DIASTOLIC DYSFUNCTION AND HEART FAILURE PHYSIOLOGY, HISTORICAL FEATURES AND CLINICAL PERSPECTIVE Medicine Resident Rounds September 28, 2007 Jacobi Hospital.

Small Platform Catheter-Based Left Ventricular Assist Device Support Suppresses Cardioprotective Beta Arrestin- Mediated Signal Transduction Keshava Rajagopal,

Gender (dis)advantages in cardiac remodelling Lessons from mice and men Female gender,myocardial remodelling and cardiac function and cardiac function.

Apoptosis-related Diseases  Insufficient apoptosis  Excessive apoptosis  Coexistence of insufficient and excessive apoptosis.

Structural and functional remodeling following pharmacologic intervention in volume overload heart failure Kristin Lewis, DVM Pathology Resident/Graduate.

Heart failure is a progressive disease The heart is unable to maintain output sufficient to meet metabolic demands Heart failure is a progressive disease.

Cell-cell Communications in Development

Excitable tissue- cardiac muscle Dr. Shafali Singh.

Effects of PG , a Matrix Metalloproteinase Inhibitor to Prevent Left Ventricular Remodeling After Acute Myocardial Infarction Effects of PG ,

Bidirectional Cavo-pulmonary Anastomosis Seoul National University Hospital Department of Thoracic & Cardiovascular Surgery.

MMP’s and Their Role in the Wound Victor L. Sylvia, Ph.D. Associate Professor Department of Orthopaedics University of Texas Health Science Center 7703.

Introduction to ROS in the Cardiovascular System John F. Keaney, Jr., M.D. UMass Medical School Worcester, MA.

1 بسم الله الرحمن الرحیم. Atrial and Ventricular Hypertrophy ECG Features and Common Causes ALI BARABADI University of Guilan.

To know more visit HeartFailure.com

Repair 2 Dr Heyam Awad FRCpath.

ANTI FIBROTIC POTENTIAL OF NONI

Dr. Hiba Wazeer Al Zou’bi

GRK2 Inhibition Reduces Post-Myocardial Infarction Cardiac Fibroblast-Mediated Adverse Remodeling Jennifer L. Philip 1, Xianyao Xu 1,Mei Han 1, Jinju Li.

Basic Science Series: Pathophysiology of Heart Failure October 27/2009.

PHARMACOLOGIC THERAPY  Standard First-Line Therapies Angiotensin-Converting Enzyme Inhibitors (ACEI) β Blockers Diuretics Digoxin  Second line Therapies.

MODULATABLE (STIMULATION) FUNCTION SECONDARY DAMAGE SUPPORT ACTIVATION OF COMPENSATORY MECHANISMS* ● Adrenergic ● RAAS ● Other INTRINSIC (RESTING) FUNCTION.

Date of download: 6/28/2016 Copyright © The American College of Cardiology. All rights reserved. From: Cardio-Pulmonary-Renal Interactions: A Multidisciplinary.

Lecture # 31 TISSUE REPAIR: REGNERATION, HEALING & FIBROSIS - 3 Dr. Iram Sohail Assistant Professor Pathology College Of Medicine Majmaah University.

Heart & Thalassemia . R.Miri,MD, Interventional Cardiologist.

Pharmacotherapy Of Cardiovascular Disorders: Heart Failure

Dr. Ahmad Hameed MBBS,DCP, M.Phil

Heart and Circulatory Failure

II- Activation of Fibroblasts and Deposition of Connective Tissue: - Laying down of connective tissue in the scar has two steps: 1. Migration and proliferation.

Cytokines within the skin & the cells that produce them

HEART FAILURE ACUTE (cardiogenic shock) CHRONIC (congestive)

Left Ventricular Dysfunction With Pulmonary Hypertension

Intracellular Action of Matrix Metalloproteinase-2 Accounts for Acute Myocardial Ischemia and Reperfusion Injury by Wenjie Wang, Costas J. Schulze, Wilma.

A Guide for the Perplexed

Section III: Neurohormonal strategies in heart failure

The pathophysiology of myocardial infarction-induced heart failure

Epicardial infarct repair with basic fibroblast growth factor–enhanced CorMatrix-ECM biomaterial attenuates postischemic cardiac remodeling Holly E.M.

Cirrhotic cardiomyopathy

Stress Pathways and Heart Failure

Volume 4, Issue 3, Pages (September 1997)

Functional evaluation of human donation after cardiac death donor hearts using a continuous isolated myocardial perfusion technique: Potential for expansion.

Eugene Braunwald JCHF 2013;1:1-20

P38 Mitogen Activated Protein Kinase Mediates Both Death Signaling and Functional Depression in the Heart Meijing Wang, MD, Ben M. Tsai, MD, Mark W.

Induction of human aortic myofibroblast-mediated extracellular matrix dysregulation: A potential mechanism of fluoroquinolone-associated aortopathy David.

Left ventricular hypertrophy in renal failure

Hepatic fibrosis: Concept to treatment

Figure 1 Ventricular end-diastolic pressure–volume relationship curves

Temporal disparity in the induction of matrix metalloproteinases and tissue inhibitors of metalloproteinases after thoracic aortic aneurysm formation

ß-blocker therapy for heart failure at the turn of the millennium

Process and mechanisms of blood vessel formation.

Sustained release of milrinone delivered via microparticles in a rodent model of myocardial infarction Hamood Al Kindi, MD, Arghya Paul, PhD, Zhipeng.

Romain Gallet et al. BTS 2016;1:14-28

Pathogenesis of idiopathic pulmonary fibrosis (IPF).

Molecular Mechanisms Underlying Cardiac Adaptation to Exercise

Patrick O’Gara et al. JIMG 2008;1:

Myocardial remodeling with aortic stenosis and after aortic valve replacement: Mechanisms and future prognostic implications William M. Yarbrough, MD,

Fig. 11. Role of endothelial dysfunction in the progression of chronic cardiac failure. The diagram depicts the four major underlying and mutually interacting.

β-Blocker Use for the Stages of Heart Failure

Presentation transcript:

LOGO Myocardial Extracellular Matrix Remodeling in Heart Failure 王小蕾高新营王洁王淳阅石琳

Myocardial remodeling Myocardial remodeling Myocardial Stress ↑ Myocyte remodeling Non-myocyte remodeling ECM remodeling

ECM remodeling in the heart Collagen I （ 80% ） III （ 10-15% ） V （ <5% ）  Components Fibronectin, Laminin, Elasin  Function: interconnecting the cardiomyocytes maintaining ventricular shape, size, stiffness Normal Remodeling Caused by the MMPs The imbalance of degradation and synthesis of collagen

The MMPs and myocardial remodeling  The Matrix MetalloProteinases family(>20 kinds) Collagenases: MMP-1, MMP-8, MMP-13 Gelatinases: MMP-2, MMP-9  Abundant collagenases are present in the heart, but only 1%-2% of them are active in physiologicstatus  TIMP (Tissue Inhibitors of MetalloProteinases) What are the MMPs?

The MMPs and myocardial remodeling How do the MMPs work in the remodeling process? MMP activation Myocardial remodeling Myocardial stress ↑ Clinical evidence: a 30-fold increase in collagenase and gelatinase activity a decrease in TIMP to negligible levels

MMP activity in volume overload Model: Chronic biventricular volume overload using aorta-caval fistula rat model Result : the post-fistula patho-physiologic course 1.The initial phase: 0-2 weeks, no deaths 2.The compensated hypertrophic phase: variable duration 3.The decompensated phase:100% dead by 30 weeks Experiment

The AV fistula experiment MMP activity ＊ CVF Ventricular compliance contractilitysize Phase1 ↑ ↓in 3d ↑in 2w ↑↓↑ Phase2 - - ↑↓↑ Phase3 ↑↑↓↑ ＊ CVF: Collagen volume fraction

The AV fistula experiment Phase1: MMP activity ↑ within 12h; collagen volume fraction(CVF) ↓ by 3d, quickly ↑, above normal by 14d; ventricular dilatation and hypertrophy by 7d; ventricular compliance ↑,contractility ↓ Changes in the first phase More compliant collagen III ↑ Collagen cross-linking ↓

The AV fistula experiment Method of testing MMP activity

The AV fistula experiment MMP activation in the early stages of injury or elevated wall stress and the consequent degradation of collagen are responsible for the initiation of a progressive remodeling process that leads to heart failure. Conclusion

Role of cardiac mast cells in the activation of MMPs  In the AV fistula modle: Mast cell density: 12h~5d MMP activity: 12h~14d the compensated hypertrophy phase  Mast cell stabilizing drug effectively prevents the LV dilatation, increased compliance and decreased contractility

> Mature mast cell density Role of cardiac mast cells in the activation of MMPs remodelingnormal What is the source for the rapid increase in mature mast density ?

Role of cardiac mast cells in the activation of MMPs Mast cell degranulation secreted substances stimulate maturation of mast cell Myocardial stress ↑ The most possible source Rapid maturation of resident cardiac mast cell precursors

Role of cardiac mast cells in the activation of MMPs

Reference 1.Joseph S. Janicki, Gregory L. Brower, Jason D. Gardner, Mary F. Forman, James A. Stewart, Jr., David B. Murray and Amanda L. Chancey, Cardiac mast cell regulation of matrix metalloproteinase-related ventricular remodeling in chronic pressure or volume overload, Cardiovascular Research, Volume 69, Issue 3, 15 February 2006, Pages Anne M. Deschamps and Francis G. Spinale, Pathways of matrix metalloproteinase induction in heart failure: Bioactive molecules and transcriptional regulation, Cardiovascular Research, Volume 69, Issue 3, 15 February 2006, Pages Stefanie Gilles, Stefan Zahler, Ulrich Welsch,Christian P. Sommerhoff, Bernhard F. Becker, Release of TNF-a during myocardial reperfusion depends on oxidative stress and is prevented by mast cell stabilizers, Cardiovascular Research,2003;60:608– Baud V, Karin M. Signal transduction by tumor necrosis factor and its relatives. Trends Cell Biol 2001;11:372– 7 5.Dempsey PW, Doyle SE, He JQ, Cheng G. The signaling adaptors and pathways activated by TNF superfamily. Cytokine Growth Factor Rev 2003;14:193–209 6.Stefanie Gilles, Stefan Zahler, Ulrich Welschb,Christian P. Sommerhoff, Bernhard F. Beckera, Release of TNF-a during myocardial reperfusion depends on oxidative stress and is prevented by mast cell stabilizers, Cardiovascular Research, 60 ;2003:608– Brower GL, Henegar JR, Janicki JS. Temporal evaluation of left ventricular remodeling and function in rats with chronic volume overload. Am J Physiol Heart Circ Physiol 1996;271:H2071– 8 8.Baicu CF, Stroud JD, Livesay VA, Hapke E, Holder J, Spinale FG, et al. Changes in extracellular collagen matrix alter myocardial systolic performance. Am J Physiol Heart Circ Physiol 2003;284:H122 – 32.

LOGO